biotech

Nanotechnology and Gene Therapy Against Stage IV Lung Cancer

Filed in archive Drugs, Vaccines and Therapeutics , Gene Therapy , Nanomedicine on April 24, 2007

A preliminary clinical trial has demonstrated that an intravenuously administered nanoparticle containing the FUS1 gene shows clinical activity in stage 4 Lung Cancer Patients. FUS1 can induce apoptosis - programmed cell death - in cancer cells but is absent in those cells.
The nanoparticle delivery system consists of a plasmid gene expression cassette loaded with DNA that encodes the FUS1 protein. This is wrapped tightly in a form of cholesterol to protect it from the body's defense mechanisms. The nanoparticles accumulate mainly in the lungs, particularly in the tumors, where the genes repeatedly express FUS1 tumor-suppressing proteins.

In the study, the median survival time for all patients is 14.6 months, which is considerably longer than the seven-month median survival time for patients receiving second line therapy. More details from the MD Anderson Cancer Center.

Permalink: Nanotechnology and Gene Therapy Against Stage IV Lung Cancer

Tags: nanotechnology  nanomedicine  gene+therapy  cancer  lung+cancer  gene  therapy+against 

Vote for Nanotechnology and Gene Therapy Against Stage IV Lung Cancer:

  • Currently 9.50/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.50 out of 4 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells